Cargando…

NMO-IgG: A Specific Biomarker for Neuromyelitis Optica

Neuromyelitis optica (NMO) is an inflammatory demyelinating disease that principally targets the optic nerves and spinal cord and often leads to severe disability and occasionally life threatening respiratory failure. Although its clinical manifestations overlap with those of multiple sclerosis (MS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinshenker, Brian G., Wingerchuk, Dean M., Pittock, Sean J., Lucchinetti, Claudia F., Lennon, Vanda A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851409/
https://www.ncbi.nlm.nih.gov/pubmed/17124341
http://dx.doi.org/10.1155/2006/586306
_version_ 1782294277568593920
author Weinshenker, Brian G.
Wingerchuk, Dean M.
Pittock, Sean J.
Lucchinetti, Claudia F.
Lennon, Vanda A.
author_facet Weinshenker, Brian G.
Wingerchuk, Dean M.
Pittock, Sean J.
Lucchinetti, Claudia F.
Lennon, Vanda A.
author_sort Weinshenker, Brian G.
collection PubMed
description Neuromyelitis optica (NMO) is an inflammatory demyelinating disease that principally targets the optic nerves and spinal cord and often leads to severe disability and occasionally life threatening respiratory failure. Although its clinical manifestations overlap with those of multiple sclerosis (MS), in established cases these two conditions can be distinguished on the basis of clinical, radiological, and routine spinal fluid studies. The diagnosis in early cases or limited forms of NMO is difficult. We recently discovered a unique IgG autoantibody (NMO-IgG) that is highly specific to patients with NMO and thus a valuable diagnostic aid. Its antigen, aquaporin-4 (AQP4), is the central nervous system’s predominant water channel protein. This antibody has not yet been proven to be pathogenic, but several facts suggest that it might be, including the similarity of the immunohistochemical pattern of NMO-(AQP4) IgG binding to mouse CNS tissues to the pattern of immune complex deposition in autopsied patients’ spinal cord tissue. The spectrum of diseases identified by NMO-IgG is broader than has previously been recognized clinically and includes incomplete forms of NMO, such as recurrent transverse myelitis without optic neuritis and recurrent optic neuritis without myelitis.
format Online
Article
Text
id pubmed-3851409
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-38514092013-12-18 NMO-IgG: A Specific Biomarker for Neuromyelitis Optica Weinshenker, Brian G. Wingerchuk, Dean M. Pittock, Sean J. Lucchinetti, Claudia F. Lennon, Vanda A. Dis Markers Other Neuromyelitis optica (NMO) is an inflammatory demyelinating disease that principally targets the optic nerves and spinal cord and often leads to severe disability and occasionally life threatening respiratory failure. Although its clinical manifestations overlap with those of multiple sclerosis (MS), in established cases these two conditions can be distinguished on the basis of clinical, radiological, and routine spinal fluid studies. The diagnosis in early cases or limited forms of NMO is difficult. We recently discovered a unique IgG autoantibody (NMO-IgG) that is highly specific to patients with NMO and thus a valuable diagnostic aid. Its antigen, aquaporin-4 (AQP4), is the central nervous system’s predominant water channel protein. This antibody has not yet been proven to be pathogenic, but several facts suggest that it might be, including the similarity of the immunohistochemical pattern of NMO-(AQP4) IgG binding to mouse CNS tissues to the pattern of immune complex deposition in autopsied patients’ spinal cord tissue. The spectrum of diseases identified by NMO-IgG is broader than has previously been recognized clinically and includes incomplete forms of NMO, such as recurrent transverse myelitis without optic neuritis and recurrent optic neuritis without myelitis. IOS Press 2006 2006-11-15 /pmc/articles/PMC3851409/ /pubmed/17124341 http://dx.doi.org/10.1155/2006/586306 Text en Copyright © 2006 Hindawi Publishing Corporation.
spellingShingle Other
Weinshenker, Brian G.
Wingerchuk, Dean M.
Pittock, Sean J.
Lucchinetti, Claudia F.
Lennon, Vanda A.
NMO-IgG: A Specific Biomarker for Neuromyelitis Optica
title NMO-IgG: A Specific Biomarker for Neuromyelitis Optica
title_full NMO-IgG: A Specific Biomarker for Neuromyelitis Optica
title_fullStr NMO-IgG: A Specific Biomarker for Neuromyelitis Optica
title_full_unstemmed NMO-IgG: A Specific Biomarker for Neuromyelitis Optica
title_short NMO-IgG: A Specific Biomarker for Neuromyelitis Optica
title_sort nmo-igg: a specific biomarker for neuromyelitis optica
topic Other
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851409/
https://www.ncbi.nlm.nih.gov/pubmed/17124341
http://dx.doi.org/10.1155/2006/586306
work_keys_str_mv AT weinshenkerbriang nmoiggaspecificbiomarkerforneuromyelitisoptica
AT wingerchukdeanm nmoiggaspecificbiomarkerforneuromyelitisoptica
AT pittockseanj nmoiggaspecificbiomarkerforneuromyelitisoptica
AT lucchinetticlaudiaf nmoiggaspecificbiomarkerforneuromyelitisoptica
AT lennonvandaa nmoiggaspecificbiomarkerforneuromyelitisoptica